CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenue	$ 439,107	$ 399,472	$ 286,776
Cost of revenue	164,833	148,986	114,406
Gross profit	274,274	250,486	172,370
Operating expenses:
General and administrative	120,093	109,736	82,983
Sales and marketing	50,664	42,849	35,322
Bad debt expense	21,768	22,222	13,291
Research and development	13,994	11,206	11,101
Other charges	15,004	14,659	31,436
Total operating expenses	221,523	200,672	174,133
Income/(loss) from operations	52,751	49,814	(1,763)
Other expense:
Interest expense	(9,482)	(9,429)	(4,897)
Loss on extinguishment of debt	0	0	(543)
Loss on equity method investments	(1,298)	(246)	(384)
Other non-operating (expense)/income, net	(2,243)	1,365	(2,809)
Total other expense, net	(13,023)	(8,310)	(8,633)
Income/(loss) before income taxes	39,728	41,504	(10,396)
(Provision for)/benefit from income taxes	(9,884)	370	(6,747)
Net income/(loss)	29,844	41,874	(17,143)
Net loss attributable to noncontrolling interests	0	(946)	(1,187)
Net income/(loss) attributable to BioTelemetry, Inc.	$ 29,844	$ 42,820	$ (15,956)
Net income/(loss) per common share attributable to BioTelemetry, Inc.:
Basic	$ 0.88	$ 1.31	$ (0.53)
Diluted	$ 0.82	$ 1.20	$ (0.53)
Weighted average number of common shares outstanding:
Basic	33,948	32,709	30,386
Dilutive common stock equivalents	2,492	3,074	0
Diluted	36,440	35,783	30,386